The FDA on May 19, 2023 granted accelerated approval to EPKINLY® for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. EPKINLY® is a product of Genmab US, Inc.
Bottom Ad
Advertisement
Subscribe
